These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 11961894)

  • 41. A new approach to modelling the relationship between in vitro and in vivo drug dissolution/absorption.
    Dunne A; O'Hara T; Devane J
    Stat Med; 1999 Jul; 18(14):1865-76; discussion 1877. PubMed ID: 10407257
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A biorelevant dissolution stress test device - background and experiences.
    Garbacz G; Klein S; Weitschies W
    Expert Opin Drug Deliv; 2010 Nov; 7(11):1251-61. PubMed ID: 20977290
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-amylose carboxymethyl starch matrices for oral sustained drug-release: in vitro and in vivo evaluation.
    Nabais T; Brouillet F; Kyriacos S; Mroueh M; Amores da Silva P; Bataille B; Chebli C; Cartilier L
    Eur J Pharm Biopharm; 2007 Mar; 65(3):371-8. PubMed ID: 17275270
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dissolution test development for complex veterinary dosage forms: oral boluses.
    Fahmy R; Marnane B; Bensley D; Hollenbeck RG
    AAPS PharmSci; 2002; 4(4):E35. PubMed ID: 12646007
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biopharmaceutical characterization of sotalol-containing oral immediate release drug products.
    Alt A; Potthast H; Moessinger J; Sickmüller B; Oeser H
    Eur J Pharm Biopharm; 2004 Jul; 58(1):145-50. PubMed ID: 15207548
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In-vitro dissolution methods for controlled release parenterals and their applicability to drug-eluting stent testing.
    Seidlitz A; Weitschies W
    J Pharm Pharmacol; 2012 Jul; 64(7):969-85. PubMed ID: 22686343
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system.
    Lindenberg M; Kopp S; Dressman JB
    Eur J Pharm Biopharm; 2004 Sep; 58(2):265-78. PubMed ID: 15296954
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Applying Biopharmaceutical Classification System (BCS) Criteria to Predict Oral Absorption of Drugs in Dogs: Challenges and Pitfalls.
    Papich MG; Martinez MN
    AAPS J; 2015 Jul; 17(4):948-64. PubMed ID: 25916691
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dissolution testing of orally disintegrating tablets.
    Kraemer J; Gajendran J; Guillot A; Schichtel J; Tuereli A
    J Pharm Pharmacol; 2012 Jul; 64(7):911-8. PubMed ID: 22686339
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Modeling and Monte Carlo simulations in oral drug absorption.
    Dokoumetzidis A; Kosmidis K; Argyrakis P; Macheras P
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):200-5. PubMed ID: 15733215
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment.
    Tannergren C; Bergendal A; Lennernäs H; Abrahamsson B
    Mol Pharm; 2009; 6(1):60-73. PubMed ID: 19183105
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Insight into the Development of Dissolution Media for BCS Class II Drugs: A Review from Quality Control and Prediction of In Vivo Performance Perspectives.
    Wu C; Liu Y; He Z; Sun J
    Curr Drug Deliv; 2016; 13(7):1004-1020. PubMed ID: 26725724
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of in vivo dissolution behavior and GI transit of griseofulvin, a BCS class II drug.
    Fujioka Y; Metsugi Y; Ogawara K; Higaki K; Kimura T
    Int J Pharm; 2008 Mar; 352(1-2):36-43. PubMed ID: 18037251
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro dissolution absorption system (IDAS2): Use for the prediction of food viscosity effects on drug dissolution and absorption from oral solid dosage forms.
    Silchenko S; Nessah N; Li J; Li LB; Huang Y; Owen AJ; Hidalgo IJ
    Eur J Pharm Sci; 2020 Feb; 143():105164. PubMed ID: 31760121
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmaceutical product development technologies based on the biopharmaceutical classification system.
    Jain D; Pathak D; Pathak K
    Pharmazie; 2009 Aug; 64(8):483-90. PubMed ID: 19746834
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmaceutical approaches to colon targeted drug delivery systems.
    Chourasia MK; Jain SK
    J Pharm Pharm Sci; 2003; 6(1):33-66. PubMed ID: 12753729
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mechanism-based prediction of particle size-dependent dissolution and absorption: cilostazol pharmacokinetics in dogs.
    Willmann S; Thelen K; Becker C; Dressman JB; Lippert J
    Eur J Pharm Biopharm; 2010 Sep; 76(1):83-94. PubMed ID: 20554023
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): theoretical basis and practical examples.
    Papadopoulou V; Valsami G; Dokoumetzidis A; Macheras P
    Int J Pharm; 2008 Sep; 361(1-2):70-7. PubMed ID: 18614303
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regulatory aspects of drug dissolution from a European perspective.
    Graffner C
    Eur J Pharm Sci; 2006 Nov; 29(3-4):288-93. PubMed ID: 16950606
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro-in vivo-in silico approach in biopharmaceutical characterization of ibuprofen IR and SR tablets.
    Beloica S; Cvijić S; Bogataj M; Parojčić J
    Eur J Pharm Sci; 2015 Jul; 75():151-9. PubMed ID: 25861718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.